About: MDX-1097     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : dbo:Drug, within Data Space : dbpedia.org associated with source document(s)
QRcode icon
http://dbpedia.org/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FMDX-1097

MDX-1097 (also called IST-1097 or KappaMab) is a monoclonal antibody therapy being assessed in Phase IIb clinical trials as a treatment for multiple myeloma, a type of white blood cell cancer. It is a chimeric version of the mouse monoclonal antibody K-1-21. MDX-1097 targets kappa free immunoglobulin light chains which are found on the surface of some kappa light chain-restricted myeloma cells. MDX-1097 was originally developed by scientists at Immune System Therapeutics Ltd. In 2015, Haemalogix Pty Ltd acquired the rights to MDX-1097 and are now taking it through late stage clinical testing.

AttributesValues
rdf:type
rdfs:label
  • MDX-1097 (en)
rdfs:comment
  • MDX-1097 (also called IST-1097 or KappaMab) is a monoclonal antibody therapy being assessed in Phase IIb clinical trials as a treatment for multiple myeloma, a type of white blood cell cancer. It is a chimeric version of the mouse monoclonal antibody K-1-21. MDX-1097 targets kappa free immunoglobulin light chains which are found on the surface of some kappa light chain-restricted myeloma cells. MDX-1097 was originally developed by scientists at Immune System Therapeutics Ltd. In 2015, Haemalogix Pty Ltd acquired the rights to MDX-1097 and are now taking it through late stage clinical testing. (en)
dcterms:subject
Wikipage page ID
Wikipage revision ID
Link from a Wikipage to another Wikipage
sameAs
dbp:wikiPageUsesTemplate
CAS number
synonyms
  • IST-1097; KappaMab (en)
type
  • mab (en)
has abstract
  • MDX-1097 (also called IST-1097 or KappaMab) is a monoclonal antibody therapy being assessed in Phase IIb clinical trials as a treatment for multiple myeloma, a type of white blood cell cancer. It is a chimeric version of the mouse monoclonal antibody K-1-21. MDX-1097 targets kappa free immunoglobulin light chains which are found on the surface of some kappa light chain-restricted myeloma cells. MDX-1097 was originally developed by scientists at Immune System Therapeutics Ltd. In 2015, Haemalogix Pty Ltd acquired the rights to MDX-1097 and are now taking it through late stage clinical testing. (en)
gold:hypernym
prov:wasDerivedFrom
page length (characters) of wiki page
CAS number
  • 1793022-75-9
foaf:isPrimaryTopicOf
is Link from a Wikipage to another Wikipage of
is Wikipage redirect of
is foaf:primaryTopic of
Faceted Search & Find service v1.17_git139 as of Feb 29 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (62 GB total memory, 43 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software